The Effects of TMZ on Diabetic Nephropathy

NCT05147194 | Unknown Phase 2

• 1 other identifier: TJ-DN-TMZ
• Study Type: interventional
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

With the improvement of people's living standard, the prevalence of Diabetes is increasing year by year. In present, 350 million people worldwide are suffering from diabetes, and by 2035, there will be as high as 600 million. Diabetes causes a variety of complications, including diabetic nephropathy, which is one of the most common complications of Diabetes. Diabetic nephropathy is a microvascular complication of diabetes. Microalbuminuria and glomerular filtration rate decrease are the main manifestation. Even more, it can progress to end-stage renal changes. Data showed that diabetic nephropathy accounts for about 40% of patients with end-stage renal disease receiving renal replacement therapy. However, the treatment of diabetic nephropathy is still lacking. In the past 40 years, few drugs have been proven to ameliorate the progression of diabetic nephropathy. Even though, the renal function of a large number of diabetic nephropathy patients is gradually deteriorating. Therefore, it is urgent to find a therapeutic drug that acts on different targets. Trimetazidine is a piperazine derivative. It is mainly used in the treatment of stable angina pectoris. Its safety has been well verified. In recent years, the role of trimetazidine in acute renal damage has been widely reported. A large number of studies have shown that trimetazidine can reduce the effect of contrast agent on renal function and reduce the incidence of contrast nephropathy. There fore, Trimetazidine is a promising drug for delaying the progression of diabetic nephropathy.

Conditions

Diabetic Nephropathies

Outcome Measures

Primary Outcomes (1)

• Ratio of UACR levels at 6 months to baseline UACR

  UACR(6 M)/UACR（base）

  6 month

Secondary Outcomes (6)

• Serum creatinine

  6 month

• 24h urine protein level

  6 month

• Proportion of patients with UACR>300 mg/g in the population at 6 months

  6 month

• Proportion of patients with UACR >30mg/g and <300 mg/g in the population at 6 months

  6 month

• Ratio of UACR levels at 3 months to baseline UACR

  3 month

Study Arms (2)

Control group

NO INTERVENTION

Blank group

Trimetazidine group

EXPERIMENTAL

The participates received treatments of trimetazidine

Drug: Trimetazidine

Interventions

Trimetazidine DRUG

Oral，35mg bid

Trimetazidine group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Older than 18 years of age;
• Type 2 diabetes mellitus;
• EGFR ≥30 to \<90 ml/min/1.73 m2;
• Urinary albumin creatinine ratio (UACR) ≥ 30 mg/g;

You may not qualify if:

• Women who are already pregnant or planning to become pregnant;
• SBP \>180mmHg and/or DBP \>110mmHg;
• UACR ≥ 3000 mg/g
• Other non-diabetic renal diseases (such as polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.);
• NYHA cardiac function grade III or above
• Those who have a history of cancer or are currently suffering from cancer;
• Receiving immunosuppressant, cytotoxic or other immunosuppressive therapy in the first 6 months;
• Patients with acute coronary syndrome, acute cardiac insufficiency or severe cerebrovascular disease in the previous month;
• Patients refused to comply with the requirements of the study to complete the study;
• In the investigator's judgment, the patient is unable to complete the study or comply with the requirements of the study (for management reasons or other reasons);

Sponsors & Collaborators

• Tongji Hospital: lead

MeSH Terms

Conditions

Diabetic Nephropathies

Interventions

Trimetazidine

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2021
• First Posted: December 7, 2021
• Study Start: January 1, 2022
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: December 7, 2021

Record last verified: 2021-11